Sun Pharmaceutical to adopt a 'disciplined' approach to M&A: Dilip Shanghvi

Asked about the strategic priorities in the US, he added: "Not only the US, but we have interest in selling innovative medicines globally... for emerging markets we are looking at tuck-ins or smaller acquisitions which we can look at integrating with our existing business to get scale in the emerging markets." Shanghvi added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g2ykR0J
via IFTTT